Plain-English translation of NCT07356778 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , given as injections every 3 weeks, can help people with rare unrepaired heart defects (like holes between heart chambers) who also have dangerously high blood pressure in their lung arteries. You would receive the medication alongside your regular lung disease medicines. In earlier studies, this treatment improved how far people could walk and how well their hearts and lungs worked, but people with your specific heart condition weren't included before.
Many people with unrepaired heart defects develop severe, treatment-resistant lung artery disease that standard medications don't fully control. This trial exists to find out whether this new medication can safely and effectively help this group of patients, who have been largely left out of previous research.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at the start, at week 12, and at week 24 (6 months total). At each visit, you'll have blood tests, walk for 6 minutes to measure how far you can go, complete questionnaires about how you're feeling, and have heart and lung assessments. Two-thirds of participants will receive the new injection every 3 weeks in addition to their regular medicines, while one-third will continue with standard care alone. The study team will monitor your blood counts carefully throughout, since the medication can affect them.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Japan